

Accepted Manuscript

Anti-Tumor Necrosis Factor with a Glyco-engineered Fc Region Has Increased Efficacy in Mice with Colitis

Felicia M. Bloemendaal, Alon D. Levin, Manon E. Wildenberg, Pim J. Koelink, Bradford L. McRae, Jochen Salfeld, Jenifer Lum, Marijn van der Neut Kolfshoten, Jill W. Claassens, Remco Visser, Arthur Bentlage, Geert R.A.M. D'Haens, J. Sjef Verbeek, Gestur Vidarsson, Gijs R. van den Brink

PII: S0016-5085(17)35949-8
DOI: [10.1053/j.gastro.2017.07.021](https://doi.org/10.1053/j.gastro.2017.07.021)
Reference: YGAST 61309

To appear in: *Gastroenterology*
Accepted Date: 20 July 2017

Please cite this article as: Bloemendaal FM, Levin AD, Wildenberg ME, Koelink PJ, McRae BL, Salfeld J, Lum J, van der Neut Kolfshoten M, Claassens JW, Visser R, Bentlage A, D'Haens GRAM, Verbeek JS, Vidarsson G, van den Brink GR, Anti-Tumor Necrosis Factor with a Glyco-engineered Fc Region Has Increased Efficacy in Mice with Colitis, *Gastroenterology* (2017), doi: 10.1053/j.gastro.2017.07.021.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Anti-Tumor Necrosis Factor with a Glyco-engineered Fc Region Has Increased Efficacy in Mice with Colitis

Felicia M. Bloemendaal^{1†}, Alon D. Levin^{1,2†}, Manon E. Wildenberg¹, Pim J. Koelink¹, Bradford L. McRae³, Jochen Salfeld³, Jenifer Lum⁴, Marijn van der Neut Kolfsochoten⁵, Jill W. Claassens⁶, Remco Visser⁷, Arthur Bentlage⁷, Geert R.A.M. D'Haens², J. Sjef Verbeek⁶, Gestur Vidarsson⁷, Gijs R. van den Brink^{1,2,8*}

¹Tytgat Institute for Liver and Intestinal Research, Academic Medical Center, The Netherlands

²Department of Gastroenterology and Hepatology, Academic Medical Center, The Netherlands

³AbbVie Bioresearch Center, Worcester, MA, USA

⁴Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands

⁵Janssen Infectious Diseases and Vaccines, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.

⁶Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands

⁷Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands

⁸GlaxoSmithKline, Medicines Research Center, Stevenage, UK

†These authors contributed equally

Short title: Hypo-fucosylated anti-TNF has superior therapeutic potential

Funding: This study was supported by unrestricted research grants from AbbVie and from the Janssen Prevention Center of Janssen Vaccines & Prevention BV, Leiden, the Netherlands, part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Abbreviations:

mAbs, monoclonal antibodies; Fc γ R, Fc γ -receptors; IBD, inflammatory bowel disease
RA; rheumatoid arthritis; MLR, mixed lymphocyte reaction

Download English Version:

<https://daneshyari.com/en/article/8727502>

Download Persian Version:

<https://daneshyari.com/article/8727502>

[Daneshyari.com](https://daneshyari.com)